Virological and immunological characterization of novel NYVAC-Based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles

Journal of Virology

Volumn 89, Issue 2, 2015, Pages 970-988

  Perdiguero, Beatriz ^a   Gómez, Carmen Elena ^a   Cepeda, Victoria ^a   Sánchez Sampedro, Lucas ^a   García Arriaza, Juan ^a   Mejías Pérez, Ernesto ^a   Jiménez, Victoria ^a   Sánchez, Cristina ^a   Sorzano, Carlos Óscar S ^a   Oliveros, Juan Carlos ^a   Delaloye, Julie ^b   Roger, Thierry ^b   Calandra, Thierry ^b   Asbach, Benedikt ^c   Wagner, Ralf ^c   Kibler, Karen V ^d   Jacobs, Bertram L ^d   Pantaleo, Giuseppe ^b   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; POL PROTEIN; PROTEIN P17; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL INTERACTION; CELL SURFACE; CHICKEN; CONTROLLED STUDY; ELECTRON MICROSCOPY; EMBRYO; FIBROBLAST; GENE INSERTION; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INOCULATION; MORPHOGENESIS; MOUSE; NEWBORN; NONHUMAN; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; PROCEDURES; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHICKENS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84920855652     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02469-14     Document Type: Article

References (40)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
2. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M. 2011. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11:189-217. http://dx.doi.org/10.2174/156652311795684731.
3. Gomez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. 2012. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 8:1192-1207. http://dx.doi.org/10.4161/hv.20778.
4. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, van der Hoeven J, Meignier B, Riviere M, Languet B, Paoletti E. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232. http://dx.doi.org/10.1016/0042-6822(92)90752-B.
5. Flynn BJ, Kastenmuller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, Salazar AM, Perdiguero B, Gomez CE, Wagner R, Esteban M, Park CG, Trumpfheller C, Keler T, Pantaleo G, Steinman RM, Seder R. 2011. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci USA 108:7131-7136. http://dx.doi.org/10.1073/pnas.1103869108.
6. Paoletti E. 1996. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 93:11349-11353. http://dx.doi.org/10.1073/pnas.93.21.11349.
7. Perkus ME, Tartaglia J, Paoletti E. 1995. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol 58:1-13.
8. Garcia-Arriaza J, Esteban M. 30 October 2014. Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother http://dx.doi.org/10.4161/hv.28974.
9. Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, Hill AV, Gilbert SC. 2008. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 3:e1638. http://dx.doi.org/10.1371/journal.pone.0001638.
10. Falivene J, Del Medico Zajac MP, Pascutti MF, Rodriguez AM, Maeto C, Perdiguero B, Gomez CE, Esteban M, Calamante G, Gherardi MM. 2012. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One 7:e32220. http://dx.doi.org/10.1371/journal.pone.0032220.
11. Garcia-Arriaza J, Arnaez P, Gomez CE, Sorzano CO, Esteban M. 2013. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS One 8:e66894. http://dx.doi.org/10.1371/journal.pone.0066894.
12. Garcia-Arriaza J, Gomez CE, Sorzano CO, Esteban M. 2014. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of MVA expressing HIV-1 antigens. J Virol 88:3392-3410. http://dx.doi.org/10.1128/JVI.02723-13.
13. Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M. 2010. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5:e12395. http://dx.doi.org/10.1371/journal.pone.0012395.
14. Garcia-Arriaza J, Najera JL, Gomez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M. 2011. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6:e24244. http://dx.doi.org/10.1371/journal.pone.0024244.
15. Perdiguero B, Gomez CE, Najera JL, Sorzano CO, Delaloye J, Gonzalez-Sanz R, Jimenez V, Roger T, Calandra T, Pantaleo G, Esteban M. 2012. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One 7:e48524. http://dx.doi.org/10.1371/journal.pone.0048524.
16. Garber DA, O'Mara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, Gill K, Verma M, Yu T, Johnson B, Li B, Derdeyn CA, Ibegbu C, Altman JD, Hunter E, Feinberg MB. 2012. Deletion of specific immunemodulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86:12605-12615. http://dx.doi.org/10.1128/JVI.00246-12.
17. Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB. 2009. Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One 4:e5445. http://dx.doi.org/10.1371/journal.pone.0005445.
18. Gomez CE, Perdiguero B, Najera JL, Sorzano CO, Jimenez V, Gonzalez-Sanz R, Esteban M. 2012. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86:5026-5038. http://dx.doi.org/10.1128/JVI.06684-11.
19. Perdiguero B, Gomez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, Calandra T, Pantaleo G, Esteban M. 2013. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS One 8:e74831. http://dx.doi.org/10.1371/journal.pone.0074831.
20. Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, Sheppard NC, Bangala Y, Frachette MJ, Wagner R, Liljestrom P, Kraehenbuhl JP, Girard M, Goudsmit J, Esteban M, Heeney J, Sattentau Q, McCormack S, Babiker A, Pantaleo G, Weber J. 2008. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-Cundertaken by the EuroVacc Consortium. Vaccine 26:3153-3161. http://dx.doi.org/10.1016/j.vaccine.2008.03.083.
21. McCormack S, Stohr W, Barber T, Bart PA, Harari A, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, Burnet S, Legg K, Brodnicki E, Wolf H, Wagner R, Heeney J, Frachette MJ, Tartaglia J, Babiker A, Pantaleo G, Weber J. 2008. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26:3162-3174. http://dx.doi.org/10.1016/j.vaccine.2008.02.072.
22. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63-77. http://dx.doi.org/10.1084/jem.20071331.
23. Harari A, Rozot V, Cavassini M, Enders FB, Vigano S, Tapia G, Castro E, Burnet S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart PA. 2012. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur J Immunol 42:3038-3048. http://dx.doi.org/10.1002/eji.201242696.
24. Bockl K, Wild J, Bredl S, Kindsmuller K, Kostler J, Wagner R. 2012. Altering an artificial Gagpolnef polyprotein and mode of ENV coadministration affects the immunogenicity of a cladeCHIVDNAvaccine. PLoS One 7:e34723. http://dx.doi.org/10.1371/journal.pone.0034723.
25. Gomez CE, Najera JL, Jimenez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljestrom P, Wagner R, Esteban M. 2007. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25:1969-1992. http://dx.doi.org/10.1016/j.vaccine.2006.11.051.
26. Ramirez JC, Gherardi MM, Esteban M. 2000. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B-and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74:923-933. http://dx.doi.org/10.1128/JVI.74.2.923-933.2000.
27. Wild J, Bieler K, Kostler J, Frachette MJ, Jeffs S, Vieira S, Esteban M, Liljestrom P, Pantaleo G, Wolf H, Wagner R. 2009. Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol 22:309-319. http://dx.doi.org/10.1089/vim.2009.0038.
28. Rodriguez D, Rodriguez JR, Rodriguez JF, Trauber D, Esteban M. 1989. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc Natl Acad Sci USA 86:1287-1291. http://dx.doi.org/10.1073/pnas.86.4.1287.
29. Liu C, Voth DW, Rodina P, Shauf LR, Gonzalez G. 1970. A comparative study of the pathogenesis of western equine and eastern equine encephalomyelitis viral infections in mice by intracerebral and subcutaneous inoculations. J Infect Dis 122:53-63. http://dx.doi.org/10.1093/infdis/122.1-2.53.
30. Prier JE (ed). 1966. Basic medical virology, p 38-77. Williams & Wilkins, Baltimore, MD.
31. Li Z, Rubin SA, Taffs RE, Merchlinsky M, Ye Z, Carbone KM. 2004. Mouse neurotoxicity test for vaccinia-based smallpox vaccines. Vaccine 22:1486-1493. http://dx.doi.org/10.1016/j.vaccine.2003.10.022.
32. Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, Gonzalez-Sanz R, Denzler K, Haddad EK, Wagner R, Sekaly RP, Tartaglia J, Pantaleo G, Jacobs BL, Esteban M. 2011. Improved NYVAC-based vaccine vectors. PLoS One 6:e25674. http://dx.doi.org/10.1371/journal.pone.0025674.
33. Doe B, Walker CM. 1996. HIV-1 p24 Gag-specific cytotoxic T-lymphocyte responses in mice. AIDS 10:793-794. http://dx.doi.org/10.1097/00002030-199606001-00015.
34. Najera JL, Gomez CE, Garcia-Arriaza J, Sorzano CO, Esteban M. 2010. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5:e11406. http://dx.doi.org/10.1371/journal.pone.0011406.
35. Roederer M, Nozzi JL, Nason MC. 2011. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79:167-174. http://dx.doi.org/10.1002/cyto.a.21015.
36. Oguiura N, Spehner D, Drillien R. 1993. Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. J Gen Virol 74(Part 7):1409-1413. http://dx.doi.org/10.1099/0022-1317-74-7-1409.
37. Freed EO. 1998. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251:1-15. http://dx.doi.org/10.1006/viro.1998.9398.
38. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, Petrilli V, Gomez CE, Perdiguero B, Tschopp J, Pantaleo G, Esteban M, Calandra T. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5:e1000480. http://dx.doi.org/10.1371/journal.ppat.1000480.
39. Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. 2014. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol 88:1809-1814. http://dx.doi.org/10.1128/JVI.02386-13.
40. Deml L, Wild J, Wagner R. 2004. Virus-like particles: a novel tool for the induction and monitoring of both T-helper and cytotoxic T-lymphocyte activity. Methods Mol Med 94:133-157.